[{"id":"fbcfc826-1fcb-464e-89b3-ff2e4a431d11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02015416","created_at":"2021-02-14T06:07:24.302Z","updated_at":"2024-07-02T16:37:18.747Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer","source_id_and_acronym":"NCT02015416","lead_sponsor":"Immune Design","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDC-G305 • glucopyranosyl lipid A (G100)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2017-08-17"}]